Loading…
← CockpitCompetitor Analysis › HLUN-A.CO H. Lundbeck A/S Class AOpen in the cockpit ↗

H. Lundbeck A/S Class AHLUN-A.COCompetitor analysis, valuation and peers

Denmark · DKK·Health Care›Pharmaceuticals: Major

Danish pharmaceutical company focused on brain diseases: depression, migraine, Parkinson's and other CNS disorders.

Momentum leader 97
Mkt cap
$9.16B
US dollars, full cap
Free float
20%
of shares outstanding
$/day
$641,742
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+9.5 pp
WACC 6.1%
Hurdle
-13 pp
Req g minus delivered
Official | Implied
BBB- / BBB-
agencies · bond market
Close · DKKDKK 60.40
1D+4.5%
1W+1.3%
1M+30.6%
3M+49.1%
6M+69.2%
YTD+66.8%
1Y+69.9%
ATR %3.3%
52w lowhigh2.6% off high

What H. Lundbeck A/S does

Danish pharmaceutical company focused on brain diseases: depression, migraine, Parkinson's and other CNS disorders.

Earns from selling its own brain-disease drugs in Europe, the US and elsewhere through its own sales forces, and from sharing profits on drugs co-developed with Otsuka, such as Rexulti. A few older products face generic competition when patents expire, so it keeps buying or licensing newer ones, including its 2024 purchase of Longboard. The Lundbeck Foundation, a Danish charity, controls it.

Products and services

  • Antidepressants (Brintellix/Trintellix)
  • Migraine treatments (Vyepti)
  • Parkinson's/movement disorder drugs
  • Rare CNS disease pipeline

Customers

  • Neurologists, psychiatrists, patients with CNS dis

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • CNS/neurology drugs

What could go right

  • Vyepti and pipeline launches
  • CNS disease demand growth

What could go wrong

  • Patent cliffs on legacy antidepressants
  • Clinical trial failure risk

Moat: narrow (IP / patents, process know-how). Deep, focused CNS drug-development expertise but faces patent expiries on key products.

Headquarters: Valby, Denmark · Founded: 1915 · Employees: 5,214

Named competitors

H. Lundbeck A/S at a glance

Size H. Lundbeck A/S (HLUN-A.CO) is a Denmark Health Care company (Pharmaceuticals: Major) with a market value of $9.16B, the 15th largest of 60 Denmark companies the cockpit tracks. Shares closed at DKK 60.40 on 18 Nov 2026.

Performance Over six months the shares gained 69.2%, against +19.2% for the median peer and +6.3% for the Denmark market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue grew 9.1% over the last twelve months (peer median +15.3%); the operating margin is 25.5% (peer median 15.4%).

Valuation It trades at 2.6× enterprise value to sales against a peer median of 5.3× (6th cheapest of 19).

Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -13 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 9.5 points above its cost of capital (6.1% WACC).

Credit H. Lundbeck A/S has 2 bonds outstanding ($1.11B), rated BBB- by the agencies and trading like BBB- at a weighted spread of 118 bp.

Relative performance

10012515021 May 202621 Aug 202618 Nov 2026HLUN-A.CO 168Peer median 118
Six months, rebased to 100: H. Lundbeck A/S against the median of its 20 peers (local-currency closes).

H. Lundbeck A/S financials

Reported figures in DKK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueDKK 26.2BDKK 24.4BDKK 22.1BDKK 19.9BDKK 18.2B
Revenue growth—+10%+11%+9%—
Gross profitDKK 20.4BDKK 19.4BDKK 17.2BDKK 15.3BDKK 14.2B
EBITDADKK 9.13BDKK 8.66BDKK 6.17BDKK 5.21BDKK 4.66B
Net incomeDKK 4.05BDKK 3.19BDKK 3.14BDKK 2.29BDKK 1.92B
Free cash flowDKK 4.75BDKK 4.34BDKK 2.90BDKK 3.81BDKK 2.07B
Capital expenditureDKK 662MDKK 618MDKK 565MDKK 501MDKK 820M
Total debtDKK 8.66BDKK 11.7BDKK 17.0BDKK 4.39BDKK 5.76B

Quarterly statements and history in the cockpit →

H. Lundbeck A/S competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+25%+50%+75%0%+20%MDGLSYRE3759PRAX4151TGTXPTGX2607RYTMGLENMARKALK-BALKS2196AMRXRGENGRFKNSACORT002821HLUN-A.CO6-month return →1-month return →
Up and to the right = strong over both horizons. H. Lundbeck A/S is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%0×10×20×30×MDGL37594151TGTXPTGX2607RYTMGLENMARKALK-BRGENKNSA002821HLUN-A.CORevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. H. Lundbeck A/S is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%+400%0%200%400%4151TGTXPTGX2607ALK-BRGENHLUN-A.COGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. H. Lundbeck A/S is the large dot.

H. Lundbeck A/S competitors and peer comparison

Head to head with its named competitors (HLUN-A.CO vs 4578.T vs TEVA vs ABBV)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
H. Lundbeck A/S HLUN-A.CO$9.16B+69%+9%26%2.6×-6.6%
Otsuka Hldgs 4578.T$39.9B+9%+11%18%2.3×1.6%
Teva Pharmaceutical Industries Limited Sponsored ADR TEVA$49.3B+23%-4%19%3.6×10.5%
AbbVie ABBV$506B+35%+11%36%8.7×-0.1%

How H. Lundbeck A/S compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

H. Lundbeck A/S against its 20 peers (data as of 18 Nov 2026)
MeasureHLUN-A.COPeer medianRank in peer set
1-month return+30.6%+4.2%2nd highest of 21
6-month return+69.2%+19.2%3rd highest of 21
Distance from 52-week high-2.6%-11.2%3rd highest of 21
Revenue growth (TTM)+9.1%+15.3%6th lowest of 20
Operating margin25.5%15.4%3rd highest of 19
EV / Sales2.6×5.3×6th cheapest of 19
Growth the price implies (Req g, 7 yrs)-6.6%17.3%3rd least demanding of 15
Growth delivered (Del g)+6.6%+9.7%2nd lowest of 15
Hurdle (Req g minus delivered)-13.2 pp+3.7 pp6th least demanding of 15
ROIC minus cost of capital+9.5 pp+1.4 pp5th highest of 19
EV / EBITDA7.4×23.1×3rd cheapest of 14
Net debt / EBITDA0.6×-0.7×6th most indebted of 14
Bond spread118 bpn/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
H. Lundbeck A/S HLUN-A.CODenmark$9.16B+69%+9%26%2.6×-6.6%+6.6%
Madrigal Pharmaceuticals MDGLUnited States$9.25B-22%+93%-11%6.0×n/an/a
Spyre Therapeutics SYREUnited States$9.64B+41%n/an/an/an/an/a
Pharmaron Beijing 3759.HKHong Kong$9.65B+48%+24%14%4.4×n/an/a
Praxis Precision Medicines PRAXUnited States$8.53B-9%-100%n/an/an/an/a
Kyowa Kirin 4151.TJapan$8.43B+9%+10%24%2.1×-4.7%+9.3%
TG Therapeutics TGTXUnited States$9.99B+66%+69%21%11.4×43.0%+426.7%
Protagonist Therapeutics PTGXUnited States$8.30B+26%+164%59%13.6×17.5%+10.0%
Shanghai Pharmaceuticals 2607.HKHong Kong$8.25B-7%+9%3%0.3×-9.7%+7.4%
Rhythm Pharmaceuticals RYTMUnited States$8.25B+31%+61%-67%29.0×n/an/a
Glenmark Pharmaceuticals GLENMARK.NSIndia$7.98B+10%0%17%4.7×27.3%+9.4%
ALK-abello A/S ALK-B.CODenmark$7.94B-8%+16%26%7.4×7.3%+12.6%
Alkermes Public ALKSUnited States$7.87B+27%+15%5%5.0×32.5%+7.3%
Shanghai Fosun Pharmaceutical (Group) 2196.HKHong Kong$7.74B-15%+10%6%2.2×19.9%+5.8%
Amneal Pharmaceuticals AMRXUnited States$7.62B+79%+9%16%3.4×17.2%+8.7%
Repligen RGENUnited States$11.0B+55%+14%9%13.5×56.9%+15.0%
Grifols GRF.MCSpain$7.48B+19%+1%16%2.4×7.1%+7.1%
Kiniksa Pharmaceuticals International KNSAUnited States$7.47B+75%+58%14%7.3×10.4%+45.5%
Corcept Therapeutics CORTUnited States$7.42B+15%+30%12%7.3×23.9%+16.6%
ONO Pharmaceutical 4528.TJapan$7.33B-2%-2%22%2.1×-6.8%+10.8%
Asymchem Laboratories (Tianjin) 002821.SZChina$7.27B+20%+18%17%5.7×n/an/a

H. Lundbeck A/S bonds and credit

H. Lundbeck A/S has 2 bonds outstanding with $1.11B face value. The agencies rate it BBB-; its bonds trade like BBB-. Weighted yield 4.26%, a spread of 118 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are H. Lundbeck A/S's main competitors?
Named competitors: Otsuka Pharmaceutical (4578.T), Teva Pharmaceutical (TEVA), UCB (private or unlisted), AbbVie (ABBV). The cockpit's measured peer set (industry) also includes Madrigal Pharmaceuticals (MDGL), Spyre Therapeutics (SYRE), Pharmaron Beijing (3759.HK), Praxis Precision Medicines (PRAX), Kyowa Kirin (4151.T), TG Therapeutics (TGTX).
Is H. Lundbeck A/S expensive compared with its peers?
On ev / sales it trades at 2.6× against a peer median of 5.3×, 6th cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -13 pp: the price already allows for a slowdown.
How has H. Lundbeck A/S stock performed?
Over six months to 18 Nov 2026 the shares returned +69.2% against +19.2% for the median peer; over one year +69.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.